Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.

Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Wang LY, Huang JF, Juo SH, Lin YC, Dai CY, Chuang WL, Yu ML.

J Gastroenterol Hepatol. 2013 Sep;28(9):1515-20. doi: 10.1111/jgh.12211.

PMID:
23560893
2.

Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.

Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ.

J Gastroenterol Hepatol. 2014 Jan;29(1):102-9. doi: 10.1111/jgh.12329.

PMID:
23829453
3.

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chen KC, Chuang WL, Kuo HT, Dai CY, Yu ML.

J Hepatol. 2012 Jan;56(1):34-40. doi: 10.1016/j.jhep.2011.03.029. Epub 2011 May 19. Erratum in: J Hepatol. 2012 May;56(5):1218.

PMID:
21703176
4.

Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.

Huang CI, Huang CF, Huang JF, Dai CY, Yeh ML, Hsieh MY, Lin ZY, Chen SC, Wang LY, Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2014 May;29(5):1012-8. doi: 10.1111/jgh.12467.

PMID:
24325201
5.

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.

Domagalski K, Pawłowska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):745-54. doi: 10.1007/s10096-012-1799-z. Epub 2013 Jan 13.

6.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
7.

Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.

Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Lin YC, Yu ML.

PLoS One. 2013;8(3):e58882. doi: 10.1371/journal.pone.0058882. Epub 2013 Mar 19.

8.

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR.

Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.

10.

Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.

Huang CF, Yeh ML, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, Hsi E, Juo SH, Dai CY, Chuang WL, Yu ML.

Antiviral Res. 2012 Feb;93(2):239-44. doi: 10.1016/j.antiviral.2011.12.002. Epub 2011 Dec 13.

PMID:
22193282
11.

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.

Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL.

Hepatology. 2011 Jan;53(1):7-13. doi: 10.1002/hep.23976.

PMID:
21254157
12.

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.

Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.

J Gastroenterol Hepatol. 2012 Sep;27(9):1467-72. doi: 10.1111/j.1440-1746.2012.07129.x.

PMID:
22432893
13.

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S.

J Gastroenterol. 2012 Sep;47(9):1014-21. doi: 10.1007/s00535-012-0560-9. Epub 2012 Mar 2.

PMID:
22382633
14.

Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.

Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH.

Gene. 2012 Oct 1;507(1):27-35. doi: 10.1016/j.gene.2012.07.026. Epub 2012 Jul 25.

PMID:
22842190
15.

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.

Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z.

Virol J. 2012 Jun 19;9:123. doi: 10.1186/1743-422X-9-123.

16.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
17.

Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.

Huang CF, Yu ML, Kao JH, Tseng TC, Yeh ML, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Liu CH.

J Clin Virol. 2013 Apr;56(4):293-8. doi: 10.1016/j.jcv.2012.11.015.

PMID:
23246359
18.

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.

Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN.

BMC Infect Dis. 2015 Mar 26;15:156. doi: 10.1186/s12879-015-0888-x.

19.

Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.

Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D'Avolio A.

Arch Virol. 2015 Aug;160(8):2009-17. doi: 10.1007/s00705-015-2482-3. Epub 2015 Jun 10.

PMID:
26060059
20.

Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.

Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.

World J Gastroenterol. 2015 Apr 7;21(13):3904-11. doi: 10.3748/wjg.v21.i13.3904.

Supplemental Content

Support Center